Abstract:Despite being mutated in 92% of TP53 mutant cancers, how mutations on p53 isoforms affect their activities remain largely unknown. Therefore, exploring the effect of mutations on p53 isoforms activities is a critical, albeit unexplored area in the p53 field. In this article, we report for the first time a mutant Δ133p53α-specific pathway which increases IL4I1 and IDO1 expression and activates AHR, a tumor-promoting mechanism. Accordingly, while WT Δ133p53α reduces apoptosis to promote DNA repair, mutant R273H also reduces apoptosis but fails to maintain genomic stability, increasing the risks of accumulation of mutations and tumor's deriving towards a more aggressive phenotype. Furthermore, using 2D and 3D spheroids culture, we show that WT Δ133p53α reduces cell proliferation, EMT, and invasion, while the mutant Δ133p53α R273H enhances all three processes, confirming its oncogenic potential and strongly suggesting a similar in vivo activity. Importantly, the effects on cell growth and invasion are independent of mutant full-length p53α, indicating that these activities are actively carried by mutant Δ133p53α R273H. Furthermore, both WT and mutant Δ133p53α reduce cellular senescence in a senescence inducer-dependent manner (temozolomide or radiation) because they regulate different senescence-associated target genes. Hence, WT Δ133p53α rescues temozolomide-induced but not radiation-induced senescence, while mutant Δ133p53α R273H rescues radiation-induced but not temozolomide-induced senescence. Lastly, we determined that IL4I1, IDO1, and AHR are significantly higher in GBMs compared to low-grade gliomas. Importantly, high expression of all three genes in LGG and IL4I1 in GBM is significantly associated with poorer patients' survival, confirming the clinical relevance of this pathway in glioblastomas. These data show that, compared to WT Δ133p53α, R273H mutation reorientates its activities toward carcinogenesis and activates the oncogenic IL4I1/IDO1/AHR pathway, a potential prognostic marker and therapeutic target in GBM by combining drugs specifically modulating Δ133p53α expression and IDO1/Il4I1/AHR inhibitors.

E3 Ubiquitin-Ligase RNF138 May Regulate P53 Protein Expression to Regulate the Self-Renewal and Tumorigenicity of Glioma Stem Cells.

The E3 Ligase Ring1 Targets P53 For Degradation And Promotes Cancer Cell Proliferation And Survival

Recent Insight into the Role of RING-finger E3 Ligases in Glioma

RNF216 Alleviates Radiation-Induced Apoptosis and DNA Damage Through Regulating Ubiquitination-Mediated Degradation of p53 in Glioblastoma

Ubiquitination of p21 by E3 ligase RNF135 promotes the proliferation of human glioblastoma cells

Downregulation of RNF138 Inhibits Cellular Proliferation, Migration, Invasion and EMT in Glioma Cells Via Suppression of the Erk Signaling Pathway

Regulation of P53 signaling in breast cancer by the E3 ubiquitin ligase RNF187

Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-B1 Target SerpinE1 in Aggressive Glioblastoma Tumors

Mir-138-5p Suppresses Glioblastoma Cell Viability and Leads to Cell Cycle Arrest by Targeting Cyclin D3.

Rho Family GTPase 1 (RND1), a Novel Regulator of P53, Enhances Ferroptosis in Glioblastoma

Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors

Small GTPase RHOE/RND3, a New Critical Regulator of NF‐κB Signalling in Glioblastoma Multiforme?

RNF122 promotes glioblastoma growth via the JAK2/STAT3/c-Myc signaling Axis

CRISPR screening of E3 ubiquitin ligases reveals Ring Finger Protein 185 as a novel tumor suppressor in glioblastoma repressed by promoter hypermethylation and miR-587

ERK and PI3K Signaling Cascades Induce Nrf2 Activation and Regulate Cell Viability Partly Through Nrf2 in Human Glioblastoma Cells.

RBBP6 maintains glioblastoma stem cells through CPSF3-dependent alternative polyadenylation

Distinct functions of wild-type and R273H mutant Δ133p53α differentially regulate glioblastoma aggressiveness and therapy-induced senescence

Correction To: Nrf2 is Required to Maintain the Self-Renewal of Glioma Stem Cells

Downregulation of Rnd3/Rhoe in Glioblastoma Patients Promotes Tumorigenesis Through Augmentation of Notch Transcriptional Complex Activity

R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3β/PTEN pathway.

mTOR Signaling Pathway Regulates Self-renewal of CD133 Positive Glioma Stem Cells